Compare Cisco Systems Inc (CSCO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs Neurocrine Biosciences Inc — how do they compare? Cisco Systems Inc trades at $121.73 (market cap $483.10B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Cisco Systems Inc is far larger — about 28.8× Neurocrine Biosciences Inc's market cap, and Cisco Systems Inc pays a 1.37% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| CSCO | NBIX | |
|---|---|---|
Market Cap | $483.10B | $16.76B |
Volume | 22,887,319 | — |
Sector | Technology | Health |
52-Week High | $130.00 | $185.50 |
52-Week Low | $66.20 | $123.10 |
Enterprise Value | $497.76B | $16.78B |
Dividend Yield | 1.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $120.43, down 0.82% on the day, amid a bullish technical outlook and strong earnings beats. The stock shows robust fundamentals with a 64.33% gross margin and consistent quarterly EPS outperformance. Recent AI cybersecurity initiatives and partner expansions fuel positive sentiment, with a consensus price target of $133.25 implying upside potential.
The outlook remains favorable given AI-driven growth catalysts and solid cash flow, though elevated valuation ratios and competitive pressures pose risks. Analyst consensus leans bullish with 52% buy ratings, supporting a constructive view for investors seeking exposure to networking and cybersecurity trends.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
